UNASSIGNED: Due to their immunosuppressive properties, mesenchymal stem cells (MSC) have been evaluated for the treatment of @entity1200 . However, the animal-derived growth supplements utilized for MSC manufacturing may lead to clinical complications. Characterization of alternative media formulations is imperative for MSC therapeutic application. @entity1 BMMSC and AdMSC were expanded in media supplemented with either @entity1 platelet lysates ( @entity4151 ), serum-free media/xeno-free FDA-approved culture medium (SFM/XF), or @entity2241 ( @entity2241 ) and the effects on their properties were investigated. The immunophenotype of resting and @entity379 primed BMMSC and AdMSC remained unaltered in all media. Both @entity4151 and SFM/XF increased the proliferation of BMMSC and AdMSC. Expansion of BMMSC and AdMSC in @entity4151 increased their differentiation, compared to SFM/XF and @entity2241 . Resting BMMSC and AdMSC, expanded in @entity2241 or SFM/XF, demonstrated potent immunosuppressive properties in both non-primed and @entity379 primed conditions, whereas @entity4151 -expanded MSC exhibited diminished immunosuppressive properties. Finally, @entity379 primed BMMSC and AdMSC expanded in SFM/XF and @entity4151 expressed attenuated levels of @entity9218 compared to @entity2241 . Herein, we provide strong evidence supporting the use of the FDA-approved SFM/XF medium, in contrast to the @entity4151 medium, for the expansion of MSC towards therapeutic applications.

Optimization of XXXX mesenchymal stem cell manufacturing: the effects of animal/xeno-free media.

@entity1 :: ('9606', 'Species') :: ['human', 'Human'] @entity4151 :: ('3956', 'Gene') :: ['HPL'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['immunological diseases'] @entity379 :: ('3458', 'Gene') :: ['IFN-y'] @entity9218 :: ('3620', 'Gene') :: ['IDO-1'] @entity2241 :: ('MESH:D005315', 'Disease') :: ['FBS', 'fetal bovine serum']
@entity1 :: (9606,Species) :: ['human']
